BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Informa
Menu

Report Library

All Reports
Datamonitor Healthcare Oncology: Waldenström Macroglobulinemia (WM) Market Spotlight

May 07, 2021

Waldenström macroglobulinemia (WM), also known as lymphoplasmacytic lymphoma, is a rare and indolent B-cell lymphoma that occurs in <2% of non-Hodgkin’s lymphoma (NHL) patients. It is characterized by large amounts of immunoglobulin M (IgM) in the blood, which can lead to hyperviscosity syndrome. WM is mainly found in the bone marrow; however, the spleen and lymph nodes may also be involved.

WM is sometimes asymptomatic, but when symptoms do occur, they may be similar to other NHL subtypes. Common symptoms of the disease include neuropathy, appetite loss, weight loss, sweats, fever, and weakness. Other symptoms of WM are abdominal swelling, vision problems, enlarged lymph nodes, digestive and nervous system symptoms, abnormal bleeding, sensitivity to cold, and infections. Due to the large amount of abnormal IgM antibody made by cancer cells, patients with WM can also develop amyloidosis, hyperviscosity syndrome, or cryoglobulins.

This Datamonitor Healthcare report contains a Market Spotlight module.

Indications Covered: Waldenstrom Macroglobulinemia (WM) / Lymphoplasmacytic Lymphoma (LPL) - NHL
Back to the top Back to the top